Showing results (341-350 of 390) with videos related to

Sort By:
Pageof 39
American Journal of Hematology|August 19, 2014
Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopeniaWilliam Beau Mitchell, Mariana P Pinheiro, Nayla Boulad, et al.
Blood Advances|September 4, 2020
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopeniaTadeusz Robak, Maciej Kaźmierczak, Isidro Jarque, et al.
The New England Journal of Medicine|November 30, 2007
Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpuraJames B Bussel, Gregory Cheng, Mansoor N Saleh, et al.
Pediatric Blood & Cancer|March 25, 2021
Quality of life is an important indication for second-line treatment in children with immune thrombocytopeniaKristin A Shimano, Cindy Neunert, James B Bussel, et al.
Haematologica|April 22, 2014
Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years durationJames B Bussel, Christina S Lee, Caroline Seery, et al.
Blood|August 5, 2020
Identification of occult cerebral microbleeds in adults with immune thrombocytopeniaNichola Cooper, Melanie A Morrison, Camelia Vladescu, et al.
Lancet (London, England)|April 23, 2016
Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled studyMichael D Tarantino, James B Bussel, Victor S Blanchette, et al.
Platelets|December 8, 2017
Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopeniaLamya Garabet, Waleed Ghanima, Christine Monceyron Jonassen, et al.
Health and Quality of Life Outcomes|February 12, 2008
Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspectiveSusan D Mathias, Sue K Gao, Kimberly L Miller, et al.
Blood|March 11, 2011
Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopeniaSarah J Barsam, Bethan Psaila, Marc Forestier, et al.
Pageof 39